Showing results (241-250 of 342) with videos related to

Sort By:
Pageof 35
The Annals of Thoracic Surgery|July 26, 2005
Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resectionEmilie Perrot, Benoit Guibert, Pierre Mulsant, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|August 1, 2014
Lack of correlation of BTNL2 polymorphism and cancer risk in sarcoidosis. BTNL2 and cancer risk in sarcoidosisMaud Gaillot-Drevon, Alain Calender, Jean Yves Blay, et al.
BMJ Open|June 16, 2022
Protocol for a prospective quasi-experimental study on SARS-CoV-2 transmission during outdoor sports events in France: the COVID-ESO projectChristelle Elias, Sandrine Nail-Billaud, Patrick Basset, et al.
Dalton Transactions (Cambridge, England : 2003)|February 28, 2012
Highly oriented surface-growth and covalent dye labeling of mesoporous metal-organic frameworksFlorian M Hinterholzinger, Stefan Wuttke, Pascal Roy, et al.
Frontiers in Stroke|January 16, 2026
Regenerative stem cell therapy for stroke in Europe (RESSTORE): a multicenter randomized controlled efficacy clinical trialLoïc Legris, Anaick Moisan, Assia Jaillard, et al.
Medicine|March 18, 2016
Observational Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase DeficiencyCécile-Audrey Durel, Achille Aouba, Boris Bienvenu, et al.
Nutrients|December 11, 2019
Energy Expenditure in Older People Hospitalized for an Acute EpisodeMarc Bonnefoy, Thomas Gilbert, Sylvie Normand, et al.
International Journal of Molecular Medicine|March 4, 2022
Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical useSandy Chevrier, Astrid Brasselet, Marion Carnet, et al.
Indian Journal of Orthopaedics|September 21, 2020
Effectiveness and Safety of the Combined Use of Tranexamic Acid: A Comparative Observational Study of 1909 CasesCharles-Hervé Vacheron, Pascal Roy, Pierre Yves Petit, et al.
Clinical Breast Cancer|July 16, 2008
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activatorFrançoise Descotes, Benjamin Riche, Simone Saez, et al.
Pageof 35